Success Metrics

Active Trials
3(38%)

Phase Distribution

Ph phase_4
3
38%
Ph not_applicable
2
25%
Ph phase_2
1
13%
Ph phase_3
1
13%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
3(42.9%)
N/ANon-phased studies
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

8

all time

Status Distribution
Active(4)
Other(4)

Detailed Status

unknown4
Recruiting2
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
3
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 21 (14.3%)
Phase 31 (14.3%)
Phase 43 (42.9%)
N/A2 (28.6%)

Trials by Status

active_not_recruiting113%
not_yet_recruiting113%
recruiting225%
unknown450%

Recent Activity

3 active trials
Showing 5 of 8
active_not_recruitingphase_2

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

NCT06139419
recruitingnot_applicable

Immuno-effect of Tα1 for Stage I NSCLC

NCT06598839
unknownphase_4

Thymosin Alpha-1 for irAE Secondary to ICIs

NCT06178146
unknownnot_applicable

Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass

NCT05487469
recruitingphase_3

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

NCT05086614
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06139419Phase 2

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Active Not Recruiting
NCT06598839Not Applicable

Immuno-effect of Tα1 for Stage I NSCLC

Recruiting
NCT06178146Phase 4

Thymosin Alpha-1 for irAE Secondary to ICIs

Unknown
NCT05487469Not Applicable

Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass

Unknown
NCT05086614Phase 3

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Recruiting
NCT04901104

Long-term Prognosis of Patients With Sepsis After Immunotherapy

Not Yet Recruiting
NCT04524169Phase 4

Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain

Unknown
NCT03448744Phase 4

Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8